Incidence of second primary malignancies (SPMs) following bispecific antibody (BsAb) therapy for lymphoid malignancies: A descriptive analysis of clinical trials
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-8071
Abstract: INTRODUCTION Bispecific antibodies (BsAbs) have emerged as transformative therapies for hematologic malignancies, with several agents now approved for relapsed/refractory acute lymphoblastic leukemia (ALL), multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). These therapies have demonstrated remarkable… read more here.
Keywords: therapy; analysis; spms following; clinical trials ... See more keywords